198 related articles for article (PubMed ID: 26310579)
1. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
Kim JR; Mathew SO; Mathew PA
Immunobiology; 2016 Jan; 221(1):31-9. PubMed ID: 26310579
[TBL] [Abstract][Full Text] [Related]
2. YY1 and a unique DNA repeat element regulates the transcription of mouse CS1 (CD319, SLAMF7) gene.
Dongre P; Mathew S; Akopova I; Gryczynski I; Mathew P
Mol Immunol; 2013 Jul; 54(3-4):254-63. PubMed ID: 23318224
[TBL] [Abstract][Full Text] [Related]
3. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes.
Lee JK; Mathew SO; Vaidya SV; Kumaresan PR; Mathew PA
J Immunol; 2007 Oct; 179(7):4672-8. PubMed ID: 17878365
[TBL] [Abstract][Full Text] [Related]
4. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.
Lee JK; Boles KS; Mathew PA
Eur J Immunol; 2004 Oct; 34(10):2791-9. PubMed ID: 15368295
[TBL] [Abstract][Full Text] [Related]
5. Repression of IFN-gamma induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling.
Tooze RM; Stephenson S; Doody GM
J Immunol; 2006 Oct; 177(7):4584-93. PubMed ID: 16982896
[TBL] [Abstract][Full Text] [Related]
6. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Veillette A; Guo H
Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
[TBL] [Abstract][Full Text] [Related]
7. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
8. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
9. Transcription of PRDM1, the master regulator for plasma cell differentiation, depends on an SP1/SP3/EGR-1 GC-box.
Mora-López F; Pedreño-Horrillo N; Delgado-Pérez L; Brieva JA; Campos-Caro A
Eur J Immunol; 2008 Aug; 38(8):2316-24. PubMed ID: 18604866
[TBL] [Abstract][Full Text] [Related]
10. Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells.
Ochiai K; Katoh Y; Ikura T; Hoshikawa Y; Noda T; Karasuyama H; Tashiro S; Muto A; Igarashi K
J Biol Chem; 2006 Dec; 281(50):38226-34. PubMed ID: 17046816
[TBL] [Abstract][Full Text] [Related]
11. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
12. GATA-3 is an important transcription factor for regulating human NKG2A gene expression.
Marusina AI; Kim DK; Lieto LD; Borrego F; Coligan JE
J Immunol; 2005 Feb; 174(4):2152-9. PubMed ID: 15699146
[TBL] [Abstract][Full Text] [Related]
13. PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.
Desai S; Bolick SC; Maurin M; Wright KL
J Immunol; 2009 Nov; 183(9):5778-87. PubMed ID: 19828640
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.
Nie K; Gomez M; Landgraf P; Garcia JF; Liu Y; Tan LH; Chadburn A; Tuschl T; Knowles DM; Tam W
Am J Pathol; 2008 Jul; 173(1):242-52. PubMed ID: 18583325
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
Zhou D; Masri S; Ye JJ; Chen S
Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
[TBL] [Abstract][Full Text] [Related]
16. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function.
Kumaresan PR; Lai WC; Chuang SS; Bennett M; Mathew PA
Mol Immunol; 2002 Sep; 39(1-2):1-8. PubMed ID: 12213321
[TBL] [Abstract][Full Text] [Related]
17. PRDM1/Blimp-1 controls effector cytokine production in human NK cells.
Smith MA; Maurin M; Cho HI; Becknell B; Freud AG; Yu J; Wei S; Djeu J; Celis E; Caligiuri MA; Wright KL
J Immunol; 2010 Nov; 185(10):6058-67. PubMed ID: 20944005
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the B lymphocyte-induced maturation protein-1 (Blimp-1) gene, mRNA isoforms and basal promoter.
Tunyaplin C; Shapiro MA; Calame KL
Nucleic Acids Res; 2000 Dec; 28(24):4846-55. PubMed ID: 11121475
[TBL] [Abstract][Full Text] [Related]
19. Blimp-1/Prdm1 alternative promoter usage during mouse development and plasma cell differentiation.
Morgan MA; Magnusdottir E; Kuo TC; Tunyaplin C; Harper J; Arnold SJ; Calame K; Robertson EJ; Bikoff EK
Mol Cell Biol; 2009 Nov; 29(21):5813-27. PubMed ID: 19737919
[TBL] [Abstract][Full Text] [Related]
20. The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type.
Liang L; Nong L; Zhang S; Zhao J; Ti H; Dong Y; Zhang B; Li T
J Exp Clin Cancer Res; 2014 Jan; 33(1):7. PubMed ID: 24438193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
